tiprankstipranks
Trending News
More News >
SelectQuote (SLQT)
NYSE:SLQT

SelectQuote (SLQT) AI Stock Analysis

Compare
403 Followers

Top Page

SLQT

SelectQuote

(NYSE:SLQT)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 4o)
Rating:50Neutral
Price Target:
$1.50
▲(7.14% Upside)
SelectQuote's overall score reflects a mix of positive revenue growth and operational improvements, offset by significant profitability and cash flow challenges. The technical indicators suggest bearish momentum, and the valuation is unattractive due to negative earnings. The earnings call provided some optimism with growth in certain segments, but unmet fiscal targets and EBITDA losses weigh heavily on the outlook.

SelectQuote (SLQT) vs. SPDR S&P 500 ETF (SPY)

SelectQuote Business Overview & Revenue Model

Company DescriptionSelectQuote (SLQT) is a leading online insurance marketplace that specializes in connecting consumers with a variety of insurance products, including life, auto, home, and health insurance. Founded in 1985, the company operates primarily in the financial services sector, leveraging technology to provide personalized insurance solutions. SelectQuote offers a platform that allows consumers to compare quotes from multiple insurance carriers, helping them to find the best policies to meet their needs.
How the Company Makes MoneySelectQuote generates revenue primarily through commissions earned on the sale of insurance policies. The company partners with numerous insurance carriers, receiving a commission for each policy sold through its platform. This commission-based model allows SelectQuote to monetize its extensive customer base effectively. Additionally, the company may earn referral fees for directing customers to specific insurance providers. SelectQuote's focus on providing a transparent and user-friendly experience attracts a wide audience, contributing to its revenue growth. The company also invests in marketing and technology to enhance its services and expand its reach within the insurance marketplace.

SelectQuote Earnings Call Summary

Earnings Call Date:Nov 06, 2025
(Q1-2026)
|
% Change Since: |
Next Earnings Date:Feb 09, 2026
Earnings Call Sentiment Neutral
SelectQuote experienced both positive and negative trends during the fiscal first quarter. The company achieved significant revenue growth in its consolidated and Life Insurance business, alongside operational achievements with the new Kansas facility. However, it faced challenges with declines in Senior segment revenues due to policy changes and a significant EBITDA impact in Healthcare Services caused by reimbursement rate adjustments. These challenges have led to unmet fiscal targets, impacting overall sentiment.
Q1-2026 Updates
Positive Updates
Consolidated Revenue Growth
SelectQuote generated consolidated revenue of $329 million, representing a 13% growth over the same period a year ago, driven by strong growth in Healthcare Services.
Life Insurance Business Growth
Revenues expanded nearly 20% in the Life Insurance segment, driven by balanced growth in term life and final expense policies.
New Kansas Facility
The new Kansas facility is ramping as planned, delivering efficiency gains in line with expectations.
SelectRx Clinical Value
SelectRx improves medication adherence and health outcomes, reducing hospital days by around 20% for members, which benefits the healthcare system.
Negative Updates
Senior Revenue Decline
Senior revenues were $59 million compared to $93 million a year ago, driven by a 32% fewer policies due to changes in beneficiary eligibility requirements.
Healthcare Services EBITDA Impact
First quarter Healthcare Services EBITDA was impacted by a change in drug reimbursement rates with a SelectRx PBM partner, affecting the first half of the fiscal year by approximately $20 million.
Consolidated EBITDA Loss
Quarterly EBITDA was negative $32 million, below the guided loss range of $25 million to $30 million due to SelectRx margin dynamics.
Unmet Fiscal Targets
SelectQuote no longer anticipates reaching its $50 million EBITDA target for fiscal '26, aiming instead for an annualized run rate of $40 million to $50 million by year-end.
Company Guidance
During the SelectQuote fiscal first quarter earnings call, several key metrics and guidance were highlighted. The company reported consolidated revenue of $329 million, marking a 13% year-over-year increase, primarily driven by growth in Healthcare Services. However, the Senior segment experienced a 37% decline in revenue to $59 million due to changes in beneficiary eligibility requirements during the special election period, leading to a negative EBITDA of $21 million. Despite this, the company is optimistic about the upcoming Annual Enrollment Period (AEP) and expects to exit fiscal 2026 with an annualized EBITDA run rate between $40 million and $50 million. Additionally, SelectQuote faced a $20 million headwind in Healthcare Services due to a change in drug reimbursement rates from a pharmacy benefit manager (PBM) partner, impacting first and second quarter EBITDA margins. The company remains confident in reaching a longer-term agreement with the PBM, expecting normalized reimbursement rates by January 1, 2026. Overall, SelectQuote maintained its fiscal 2026 financial outlook, projecting revenues of $1.65 billion to $1.75 billion and adjusted EBITDA between $120 million and $150 million, with expectations to be operating cash flow positive for the year.

SelectQuote Financial Statement Overview

Summary
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
50
Neutral
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

SelectQuote Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.40
Price Trends
50DMA
1.67
Negative
100DMA
1.86
Negative
200DMA
2.28
Negative
Market Momentum
MACD
-0.07
Negative
RSI
37.49
Neutral
STOCH
12.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLQT, the sentiment is Negative. The current price of 1.4 is below the 20-day moving average (MA) of 1.41, below the 50-day MA of 1.67, and below the 200-day MA of 2.28, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 37.49 is Neutral, neither overbought nor oversold. The STOCH value of 12.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLQT.

SelectQuote Peers Comparison

Overall Rating
UnderperformOutperform
Sector (―)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$134.44M117.795.88%16.79%
57
Neutral
$31.48M12.524.56%19.30%-17.56%
50
Neutral
$234.04M-44.4815.11%13.16%
44
Neutral
$37.50M-0.15-142.05%7.56%-344.04%
44
Neutral
$6.41M-0.28-146.43%-6.84%97.23%
43
Neutral
$11.96M-0.15-11.18%624.24%85.46%
* Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SLQT
SelectQuote
1.33
-1.79
-57.37%
EHTH
Ehealth
4.37
-3.55
-44.82%
RELI
Reliance Global Group
0.65
-2.37
-78.48%
HUIZ
Huize Holding
3.12
-0.72
-18.75%
TIRX
Tian Ruixiang Holdings
0.45
-8.40
-94.92%
GOCO
GoHealth
2.33
-10.43
-81.74%

SelectQuote Corporate Events

Executive/Board ChangesShareholder Meetings
SelectQuote Holds 2025 Annual Stockholders Meeting
Neutral
Nov 14, 2025

On November 11, 2025, SelectQuote, Inc. held its 2025 Annual Meeting of Stockholders, where 114,443,928 shares were represented. During the meeting, two Class III directors were elected, Deloitte & Touche LLP was ratified as the independent accounting firm for the fiscal year ending June 30, 2026, and the compensation for the company’s named executive officers was approved.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 21, 2025